Eric S. Daar, M.D.
Eric Daar, MD is a Professor of Medicine at the David Geffen School of Medicine at UCLA, Chief of the Division of HIV Medicine at Harbor-UCLA Medical Center, and Vice Chair of the Board of Directors of the Lundquist Institute at Harbor-UCLA Medical Center. Dr. Daar completed his clinical and research fellowship at Cedars-Sinai Medical Center. His research focuses on pathogenesis and treatment of acute and chronic HIV infection, management of complications of HIV infection, novel strategies for addressing engagement in HIV care, and developing strategies for prevention and treatment of COVID-19.
Dr. Daar has led numerous investigator-initiated trials, as well as leading the Harbor-UCLA Clinical Research Site of the Advancing Clinical Therapeutics Globally (ACTG) network, formerly known as the AIDS Clinical Trials Group. He has participated on, and led scientific research committees as well as protocols for the ACTG network, including his current role on the Executive Committee. He was also Vice Chair of the ACTIV-2 program, a public-private venture funded through the NIH to explore novel therapeutics for non-hospitalized patients with COVID-19. He currently serves on the Department of Health and Human Services Adult and Adolescent HIV Treatment Guidelines panel, and the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guidelines panel. He also served on the NIH COVID-19 Treatment Guidelines. His research has resulted in him being author on more than 300 manuscripts published in the peer-reviewed literature.
Areas of Expertise
- HIV immune and neuropathogenesis
- HIV treatment strategies
- Management of HIV treatment failure
- COVID-19 treatment and prevention
Education
- B.A., University of California, Los Angeles
- M.D., Georgetown University School of Medicine
- Internship and Residency, Internal Medicine, Cedars-Sinai Medical Center
- Fellowship, Infectious Diseases, Cedars-Sinai Medical Center
Publications
Notable recent publications:
- Evering TH, Chew K, Giganti M, Moser C, Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio R, Margolis D, Zhu Q, Ma J, Zhong L, Yan L, D’Adrea Nores U, Hoover K, Mocherla B, Mocherla B, Choudhary MC, Deo R, Ritz J, Fischer W, Fletcher CV, Li JZ, Hughes MD, Smith D, Daar ES, for the ACTIV-2/A5401 Study Team. Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in non-hopspitalized patients with COVID. Ann Intern Med 2023; 176:658-666 [PMID: 37068272].
- Letendre SL, Chen H, McKhann A, Roa J, Vecchio A, Daar ES, Berzins B, Hunt PW, Marra CM, Campbell TB, Coombs RW, Ma Q, Swaminathan S, Macatangay BJC, Morse G, Miller T, Rusin D, Greninger AL, Ha B, Alston-Smith B, Robertson K (posthumous), Paul R, Spudich S, A5324 Study Team. Antiretroviral therapy intensification for neurocognitive impairment in Human Immunodeficiency Virus. Clin Infect Dis 2023 ; 77:866-874 [PMID: 37183889].
- Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, Wohl DA, Daar ES, Hughes MD for the ACTIV-2/A5401 Study Team. ACTIV-2: A platform trial for the evaluation of novel therapeutics for the treatment of early COVID-19 in outpatients. J Infect Dis 2023; 228:S77-S82 S91 [PMID: 37650231].
- Crowell TA, Ritz J, Zheng L, Naqvi A, Cyktor JC, Puleo J, Clagett B, Lama JR, Kanyama C, Little SJ, Cohn SE, Riddler SA, Collier AC, Heath SL, Tantivitayakul P, Grinsztejn B, Arduino RC, Rooney JF, van Zyl GU, Coombs RW, Fox L, Ananworanich J, Eron JJ, Sieg SF, Mellors JW, Daar ES for the AIDS Clinical Trials Group (ACTG) A5354/EARLIER Study Team. Impact of antiretoviral therapy during acute or early HIV infection on virologic and immunologic outcomes: Results from a multinational clinical Trials. AIDS 2024; 38:1141-1152 [PMID: 38489580].
- Chew KW, Taiwo BO, Moser C, Daar ES, Wohl DA, Ritz J, Javan AC, Li JZ, Fischer W, Greninger AL, Bausch C, Luke T, Call R, Neytman G, Giganti MJ, Fletcher CV, Hughes MD, Eron JJ, Currier JS, Smith DM, for the ACTIV-2/A5401 Study Team. Safety and efficacy of SAB-185 for non-hospitaized adults with COVID-19: A randomized clinical trial. J Infect Dis 2024; doi: 10.1093/infdis/jiae369 [PMIC: 39028902].
A list of publications can be found here
Achievements
- Alpha Omega Alpha Medical Society, Washington D.C.
- Morris Press Humanism Award for Attending Staff, Cedars-Sinai Medical Center
- Golden Apple Award for Teaching Excellence, Cedars-Sinai Medical Center
- Excellence in Education Award, UCLA School of Medicine
- Commendation for Service to HIV Community, City of West Hollywood
- America’s Top Doctors, Castle Connolly Medical
- Pat Griffin Hero of the Year Award, LA Shanti Plus Program
- Outstanding HIV Physician, The Body.Com HIV Website Leadership Award
- The Founders Award, The Heart Touch Project
- Spirit of Hope Award, Being Alive Los Angeles
- Certificate of Commendation, City of West Hollywood
- Los Angeles Super Doctors
- Los Angeles HIV/AIDS Women’s Task Force Medical Provider Award
- Legends Award, The Lundquist Institute at Harbor-UCLA Medical Center
Ongoing Research Projects
- UCLA-CDU CFAR, project to support the conduct of HIV/AIDS research at UCLA and Charles Drew University
- AIDS Prevention and Treatment Clinical Trials Unit, through the ACTG with studies addressing HIV pathogenesis, treatment as well as management of other viral infections including hepatitis B, hepatitis C, SARS-CoV-2 and Mpox.
- An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among people living with HIV
© 2024 Lundquist. All rights reserved